Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes

198Citations
Citations of this article
254Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Fifty years after the recognition of the Li–Fraumeni syndrome (LFS), our perception of cancers related to germline alterations of TP53 has drastically changed: (i) germline TP53 alterations are often identified among children with cancers, in particular soft-tissue sarcomas, adrenocortical carcinomas, central nervous system tumours, or among adult females with early breast cancers, without familial history. This justifies the expansion of the LFS concept to a wider cancer predisposition syndrome designated heritable TP53-related cancer (hTP53rc) syndrome; (ii) the interpretation of germline TP53 variants remains challenging and should integrate epidemiological, phenotypical, bioinformatics prediction, and functional data; (iii) the penetrance of germline disease-causing TP53 variants is variable, depending both on the type of variant (dominant-negative variants being associated with a higher cancer risk) and on modifying factors; (iv) whole-body MRI (WBMRI) allows early detection of tumours in variant carriers and (v) in cancer patients with germline disease-causing TP53 variants, radiotherapy, and conventional genotoxic chemotherapy contribute to the development of subsequent primary tumours. It is critical to perform TP53 testing before the initiation of treatment in order to avoid in carriers, if possible, radiotherapy and genotoxic chemotherapies. In children, the recommendations are to perform clinical examination and abdominal ultrasound every 6 months, annual WBMRI and brain MRI from the first year of life, if the TP53 variant is known to be associated with childhood cancers. In adults, the surveillance should include every year clinical examination, WBMRI, breast MRI in females from 20 until 65 years and brain MRI until 50 years.

References Powered by Scopus

Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?

1269Citations
N/AReaders
Get full text

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome

1145Citations
N/AReaders
Get full text

Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

671Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>

574Citations
N/AReaders
Get full text

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline <sup>☆</sup>

109Citations
N/AReaders
Get full text

Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants

107Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Frebourg, T., Bajalica Lagercrantz, S., Oliveira, C., Magenheim, R., Evans, D. G., Hoogerbrugge, N., … Hietala, M. (2020). Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes. European Journal of Human Genetics, 28(10), 1379–1386. https://doi.org/10.1038/s41431-020-0638-4

Readers over time

‘20‘21‘22‘23‘24‘25020406080

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 53

56%

Researcher 27

28%

Professor / Associate Prof. 12

13%

Lecturer / Post doc 3

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 73

61%

Biochemistry, Genetics and Molecular Bi... 34

28%

Nursing and Health Professions 7

6%

Agricultural and Biological Sciences 6

5%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0